In Brief: Organon Teknika
This article was originally published in The Gray Sheet
Organon Teknika: Grants Toyobo non-exclusive rights to use its nucleic acid amplification technology in Japan "in the fields of infectious disease screening and genetic and cancer testing, with an option to other fields of application." Teknika began selling HIV research kits using its technology in 1994 in Europe and the U.S. The agreement is "one of the first" amplification licenses granted by Organon, and "underlines that it forms an excellent alternative to polymer chain reaction amplification"...
You may also be interested in...
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.